THE SILENT PANDEMIC
Addressing Antimicrobial Resistance Through a Sustainable Marketplace

THE THREAT OF ANTIMICROBIAL RESISTANCE
A shortage of effective antibiotics puts the world at risk for future pandemics. Globally, antimicrobial resistance (AMR) is a top public health concern that we can no longer ignore.

THE GLOBE
700,000 people die from drug-resistant infections every year
10 million potential deaths from drug-resistant infections by 2050

THE U.S.
35,000 Americans die from drug-resistant infections every year
2.8 million Americans are infected by antibiotic-resistant bacteria annually

LACK OF DEVELOPMENT INCENTIVES
Manufacturers often lack incentives to develop new antibiotics because they are used sparingly—whenever medically appropriate—leading to a lower return on investment.

$800M + 10 YEARS
AVERAGE INVESTMENT in time and money to bring a new drug to market

5 OUT OF 15
APPROVED ANTIBIOTICS SHELVED
Only 15 new antibiotics earned FDA approval in the past decade. Five were shelved due to poor financial performance.

THE FOUNDATION HAS DEDICATED $100M over 5 years to address chronic infections of research budget is dedicated to pseudomonas + MRSA

3 OUT OF 7
of the most common infections in people with CF are also serious threats to the general population according to the CDC.

THE CYSTIC FIBROSIS EXPERIENCE
Respiratory infections are a hallmark of life with cystic fibrosis. Many people with cystic fibrosis live in fear of contracting an infection for which existing antibiotics are not effective.

THE FOUNDATION HAS DEDICATED

5 OUT OF 15
APPROVED ANTIBIOTICS SHELVED
Only 15 new antibiotics earned FDA approval in the past decade. Five were shelved due to poor financial performance.

STEPS TO A SUSTAINABLE MARKETPLACE
The Foundation is doing everything it can to put new infection treatments into the hands of patients, but investment in research and development alone will not solve these marketplace challenges. Finding new ways to incentivize and reward companies that bring vital new antibiotics to market are necessary for a sustainable marketplace. Congress must consider:

REIMBURSEMENT REFORMS
THAT DELINK FINANCIAL VALUE FROM USE, SUCH AS INNOVATIVE SUBSCRIPTION MODELS.

POST-MARKET INCENTIVES
TO ENSURE INNOVATORS RECEIVE A FAIR & REASONABLE RETURN ON INVESTMENT

ROBUST FUNDING
FOR GOVERNMENT AGENCIES SUCH AS NIH, BARDA, THE CDC, & FDA

CONGRESS MUST PASS LEGISLATION TO STRENGTHEN THE ANTIBIOTICS PIPELINE

THE CYSTIC FIBROSIS EXPERIENCE
Respiratory infections are a hallmark of life with cystic fibrosis. Many people with cystic fibrosis live in fear of contracting an infection for which existing antibiotics are not effective.